Stocks · News reference
The United States Patent and Trademark Office has issued Lantern Biopharma a Notice of Allowance for U.S. Patent Application No. 17/230,821, titled "Methods for the Treatment of Solid Tumor Cancers Using Illudins
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.38) by 50 percent. This is a 42.5 percent decrease over losses of $(0.40) per share from the
Read original at benzingaFiled: 2026-08-14 AccNo: 0001493152-26-037979 Size: 8 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarLantern Pharma Inc. (Nasdaq: LTRN), a clinical-stage AI-driven precision oncology company, today announced the formal creation of Open-Medicine AI (OMAI) and the execution of commercial licensing agreements between OMAI
Read original at benzingaThe study will be conducted at Rigshospitalet in Copenhagen — Denmark’s national referral center for urologic cancers — in collaboration with Professor Helle Pappot, MD, DMSc, a leading authority in the treatment of
Read original at benzinga